List of Excipients in Branded Drug PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)	paclitaxel	24979-710	ALBUMIN HUMAN
Apotex Corp	PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)	paclitaxel	60505-6230	ALBUMIN HUMAN

Generic Drugs Containing PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)

Company	Ingredient	NDC	Excipient
BluePoint Laboratories	paclitaxel	68001-651	ALBUMIN HUMAN
Meitheal Pharmaceuticals Inc	paclitaxel	71288-183	ALBUMIN HUMAN
NorthStar Rx LLC	paclitaxel	72603-408	ALBUMIN HUMAN

What are the Most Frequently-Used Excipients in PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND)?

# Of NDCs	Excipient
3	ALBUMIN HUMAN

Paclitaxel Protein-Bound Particles Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Paclitaxel protein-bound particles for injectable suspension, marketed as Abraxane, uses human albumin as both an excipient and particle-forming delivery system. The formulation eliminates Cremophor EL and ethanol, supports solvent-free intravenous administration, and enables a differentiated dosing profile. Commercial opportunities center on albumin sourcing, particle engineering, manufacturing capacity, generic competition, hospital economics, and next-generation albumin-bound oncology products.

What excipient is used in paclitaxel protein-bound particles?

The principal excipient is human albumin. The product contains paclitaxel formulated as albumin-bound nanoparticles for reconstitution and intravenous administration. It does not contain Cremophor EL, polyoxyethylated castor oil, or ethanol, which are used in conventional paclitaxel injection formulations.

Product attribute	Abraxane formulation
Active ingredient	Paclitaxel
Delivery format	Albumin-bound particles
Principal excipient	Human albumin
Dosage form	Lyophilized powder for injectable suspension
Administration	Intravenous infusion after reconstitution
Solvent system	No Cremophor EL or ethanol
Commercial originator	Abraxis BioScience; subsequently Celgene and Bristol Myers Squibb
FDA approval	January 2005
Primary use at approval	Metastatic breast cancer after failure of combination chemotherapy
Later indications	Non-small-cell lung cancer and metastatic pancreatic adenocarcinoma

The FDA label identifies albumin as a key inactive component and describes the product as paclitaxel formulated as albumin-bound particles. The albumin is not a passive filler. It participates in particle formation, drug loading, colloidal stability, reconstitution behavior and the product’s administration profile.[1]

How does albumin function in the formulation?

Albumin performs several technical functions that create formulation and manufacturing barriers.

Particle formation

Paclitaxel is poorly water-soluble. Albumin provides a protein matrix that allows paclitaxel to be processed into nanoscale particles suitable for aqueous dispersion after reconstitution. The commercial product uses a high-pressure homogenization process to produce albumin-bound particles.

Particle size, size distribution, surface characteristics and drug-to-albumin ratio affect:

• Reconstitution time
• Suspension stability
• Infusion performance
• Filterability
• Sedimentation
• Dose uniformity
• Potential aggregation
• Release and biodistribution

A competing product must reproduce the finished product’s critical quality attributes rather than simply combine paclitaxel and albumin in a vial.

Solvent elimination

Conventional paclitaxel products require solubilizing excipients, including Cremophor EL, and premedication may be used to manage hypersensitivity reactions. Abraxane’s solvent-free design removes the need for those formulation components and permits administration without the same solvent-related constraints described for conventional paclitaxel.[1]

This creates a commercial value proposition based on:

• Reduced solvent exposure
• Elimination of conventional solvent-related premedication requirements
• Shorter infusion administration than conventional paclitaxel in labeled regimens
• Higher labeled dose in selected indications
• Different administration and handling requirements

Albumin-mediated delivery

The product’s development rationale includes albumin-associated transport and tumor delivery mechanisms. Commercial claims must be separated from the formulation’s established quality attributes. Albumin binding alone does not establish identical pharmacology for a competing product. Particle size, manufacturing process and albumin source can alter the product’s behavior.

What albumin specifications matter commercially?

Albumin quality is a central procurement and regulatory issue. Relevant specifications include:

• Human origin and donor screening
• Viral safety controls
• Identity and purity
• Fatty-acid and ligand-binding profile
• Aggregates and fragments
• Residual process impurities
• Endotoxin
• Bioburden
• Moisture and residual solvents
• Lot-to-lot consistency
• Supply continuity

Albumin may be sourced from licensed plasma-derived suppliers. The manufacturer must control the albumin input as a critical raw material, even when albumin is classified as an inactive ingredient in the finished product.

The commercial risk is greater than the cost of albumin alone. A supplier change can affect particle formation, stability, reconstitution, potency, impurity profile and comparability. A dual-sourcing strategy may reduce supply risk but can trigger comparability studies, process validation and regulatory supplements.

What albumin alternatives could reduce cost?

Potential alternatives include recombinant human albumin, chemically modified albumin, plant-derived albumin and synthetic protein-mimetic materials. Each option faces a different regulatory and technical burden.

Albumin option	Commercial advantage	Principal barrier
Plasma-derived human albumin	Established regulatory history	Donor supply, viral safety and price exposure
Recombinant human albumin	Avoids plasma dependence	Comparability, scale and regulatory acceptance
Modified albumin	Tunable binding and particle properties	New excipient and product characterization burden
Synthetic polymer carrier	Potentially lower raw-material cost	Loss of albumin-linked differentiation and new safety package
Plant-derived protein	Alternative supply model	Identity, impurities, immunogenicity and consistency

For an Abraxane-like generic, changing the albumin source may create a product-development advantage only if the resulting formulation remains sufficiently comparable under the applicable abbreviated approval pathway. For a new albumin-bound oncology product, an alternative carrier could support broader formulation freedom but would likely require a more extensive clinical and nonclinical program.

What manufacturing process creates the strongest IP position?

The strongest commercial protection is likely to come from the combination of composition, particle attributes and process controls rather than from albumin as a standalone excipient.

High-pressure homogenization

The process converts paclitaxel and albumin into a controlled particulate suspension. Important process variables include:

• Homogenization pressure
• Number of passes
• Temperature
• Concentration
• Feed rate
• Albumin-to-paclitaxel ratio
• pH
• Pre-mixing conditions
• Hold times
• Lyophilization cycle

These parameters can be protected through process patents and retained as trade secrets. A patent claim covering a broad albumin-bound paclitaxel composition may be difficult to enforce against a product using different process conditions. Manufacturing know-how can remain valuable after composition patents expire.

Lyophilization and reconstitution

The product is supplied as a lyophilized powder. Commercially relevant controls include:

• Cake structure
• Collapse temperature
• Residual moisture
• Reconstitution time
• Visible and subvisible particles
• Post-reconstitution particle-size distribution
• Container closure integrity
• Stability under shipping conditions

A formulation strategy that improves reconstitution without changing clinical performance can support hospital adoption, especially in high-throughput infusion centers. Proprietary lyophilization cycles, vial configurations and reconstitution instructions may provide incremental differentiation.

What patents protect paclitaxel protein-bound particles?

The historical patent estate is associated with albumin-bound drug delivery, paclitaxel particle compositions, manufacturing methods and cancer-treatment methods. One foundational patent family includes U.S. Patent No. 5,439,686, covering compositions and methods for delivery of pharmacologic agents using albumin-associated particles.[2]

Key patent categories

Patent category	Protected subject matter	Commercial relevance
Composition patents	Paclitaxel associated with albumin particles	Core product protection
Particle patents	Size, morphology and drug loading	Supports formulation differentiation
Process patents	Homogenization and particle manufacture	Raises generic manufacturing burden
Method-of-use patents	Treatment of specified cancers and dosing regimens	Relevant to label and litigation strategy
Formulation patents	Lyophilized product, stabilizers and reconstitution	Supports lifecycle management
Manufacturing know-how	Equipment settings and in-process controls	Difficult to replicate without internal data

Patent expiration must be assessed family by family, including terminal disclaimers, patent-term adjustment, pediatric extensions and jurisdiction-specific calculations. The core early composition protection associated with U.S. Patent No. 5,439,686 expired before the current commercial period. Later patents may have covered particular uses, formulations or manufacturing approaches, but their scope and enforceability must be evaluated against the specific generic product and proposed label.[2]

The FDA Orange Book, patent assignment records, prosecution histories and litigation dockets provide the relevant product-specific record.[3-5]

When does Abraxane lose exclusivity?

Abraxane’s principal regulatory exclusivity has expired. FDA approval occurred in 2005, and the product has been exposed to generic competition through the abbreviated new drug application pathway. The product is a small-molecule drug, not a biologic, so biosimilar exclusivity rules do not apply.

Exclusivity issue	Status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary protection for the commercial product
Pediatric exclusivity	Any applicable extension is historical and expired
Core composition patent	Historical protection; early core patent expired
Method-of-use patents	May remain relevant depending on patent and indication
Generic pathway	ANDA
Biosimilar pathway	Not applicable

The practical loss of exclusivity is measured by approved generic products, Orange Book-listed patents and the scope of remaining enforceable claims. A patent can remain listed while offering limited commercial protection if a generic applicant uses a noninfringing process or omits a protected method of use.

Which companies are challenging the Abraxane franchise?

Generic manufacturers can challenge Abraxane through ANDA filings, including Paragraph IV certifications against listed patents. The competitive set includes companies developing or marketing paclitaxel protein-bound particles for injectable suspension, as well as manufacturers selling conventional paclitaxel injection and docetaxel.

The main competitive groups are:

1. Generic nab-paclitaxel manufacturers.
2. Conventional paclitaxel manufacturers.
3. Docetaxel manufacturers.
4. Novel nanoparticle or polymer-bound taxane developers.
5. Regional manufacturers in markets where patent and regulatory barriers differ.

The FDA approved generic versions of paclitaxel protein-bound particles for injectable suspension, including a Teva product, creating direct price competition with Abraxane.[6] The number of approved suppliers, launch timing, authorized-generic arrangements and supply reliability determine actual erosion more than approval status alone.

What is the Orange Book status of Abraxane?

Abraxane is listed in the FDA Orange Book under NDA 021660. Orange Book analysis should distinguish:

• Patents listed against the reference product
• Expired patents
• Unexpired patents
• Use codes
• Patent certifications submitted by ANDA applicants
• Litigation triggered by Paragraph IV certifications
• Delayed generic approval based on first-filer exclusivity

The Orange Book does not establish that every listed patent will block every generic design. It identifies the patents and uses submitted by the NDA holder under FDA listing rules. Patent strength depends on claim construction, prosecution history, infringement evidence and validity.

What generic entry risks exist?

Generic entry can affect Abraxane through several launch scenarios.

Scenario 1: One generic entrant

A single approved competitor may obtain substantial discounts while preserving a premium for the reference product. Hospitals may maintain Abraxane use where physicians value established supply and clinical familiarity.

Scenario 2: Multiple generic entrants

Multiple suppliers can produce rapid price erosion. Group purchasing organizations may shift volume to the lowest-cost product, particularly for standardized oncology protocols.

Scenario 3: Authorized generic or controlled competition

The reference sponsor may respond through an authorized generic, contracting strategy or supply agreement. This can reduce the economic incentive for independent generic launches while protecting channel access.

Scenario 4: Indication-specific substitution

A generic may enter with a label that does not include every protected use. Pharmacy substitution and payer coverage can then vary by indication. Method-of-use patents may retain practical value if a major indication is commercially important and substitution is controlled.

How does Abraxane compare with conventional paclitaxel?

Attribute	Abraxane	Conventional paclitaxel injection
Carrier	Albumin-bound particle	Solvent-based solution
Cremophor EL	No	Typically present
Ethanol	No	Typically present
Premedication burden	Different from conventional paclitaxel	Solvent-related premedication described in labeling
Formulation complexity	High nanoparticle manufacturing burden	Lower particle-engineering burden
Excipient supply risk	Albumin and particle-process dependence	Solvent and conventional excipient dependence
Generic development	Requires particle comparability	Conventional injectable equivalence pathway
Differentiation	Delivery system and administration profile	Lower-cost established taxane

Abraxane’s commercial advantage is strongest where the healthcare system values solvent avoidance, administration convenience, labeled dosing and clinical familiarity. Its disadvantage is cost, manufacturing complexity and increasing generic substitution pressure.

What commercial opportunities exist for excipient suppliers?

Albumin supply

A qualified albumin supplier can capture value through long-term contracts, redundant manufacturing sites and validated grade consistency. The most attractive position is not commodity albumin supply alone, but albumin supported by regulatory documentation, change-control management and technical assistance.

Recombinant albumin

Recombinant albumin may provide a strategic option for new albumin-bound products. The opportunity is strongest in products where plasma-derived material creates supply, perception or geographic access concerns.

Particle-engineering platforms

Contract development and manufacturing organizations can offer:

• High-pressure homogenization
• Nanoparticle process development
• Lyophilization
• Sterile vial filling
• Analytical particle characterization
• Scale-up and process validation
• Comparability packages for albumin source changes

Lifecycle extensions

Potential product extensions include:

• Ready-to-use liquid suspensions
• Smaller vial sizes to reduce wastage
• Alternate concentration formats
• Extended stability after reconstitution
• Regional packaging adaptations
• Combination products with other oncology agents
• Albumin-bound versions of poorly soluble compounds

Each extension must address the risk that a new presentation changes the regulatory product, patent position or clinical administration profile.

How strong is the patent estate for albumin-bound paclitaxel?

The estate is technically meaningful but commercially weaker than during the product’s launch period. The original platform patent created an important barrier, while later value shifted toward manufacturing control, clinical evidence, brand recognition, regulatory history and supply reliability.

Estate component	Relative strength
Broad historical albumin-particle concept	Low after expiration
Paclitaxel-specific composition claims	Depends on claim status and jurisdiction
Particle-size or process claims	Moderate if narrowly drafted and supported
Method-of-use claims	Moderate, subject to label and indication
Trade secrets	Potentially strong if process-critical
Albumin supplier controls	Strong operational barrier, not necessarily patent protection
Regulatory data and clinical familiarity	Commercially important but time-limited

A new entrant should treat the product as a combined formulation, process and regulatory challenge. Copying the active ingredient and albumin does not automatically reproduce the reference product.

What regulatory pathway applies to generic products?

Generic paclitaxel protein-bound particles generally proceed through an ANDA rather than a biosimilar application. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA requirements for the complex formulation. The key development issues include:

• Same active ingredient
• Same dosage form and route
• Comparable particle characteristics
• Comparable albumin content and function
• Reconstitution performance
• Stability
• Impurity profile
• Sterility and endotoxin controls
• Labeling and patent certifications

The FDA’s product-specific guidance and approval history are central to development strategy. Complex injectable suspensions can require more extensive characterization than conventional solutions because particle attributes can influence product performance.[7]

What licensing opportunities exist?

Licensing opportunities are concentrated in three areas:

Albumin-bound oncology assets

A developer with a poorly soluble cytotoxic or targeted agent may license an albumin-particle platform to avoid developing a new solvent system.

Regional rights

Rights in Asia-Pacific, Latin America, the Middle East and selected European markets may have different value because patent expiry, regulatory approval and procurement practices vary by country.

Manufacturing licenses

A license to an established particle-manufacturing process can reduce development time for regional suppliers. The agreement should address albumin sourcing, quality changes, process validation, technology transfer, field of use and supply obligations.

The historical commercialization path demonstrates the value of platform licensing. Abraxis developed and commercialized Abraxane before its acquisition by Celgene, which was later acquired by Bristol Myers Squibb.[8]

What patent litigation and settlement issues affect generic launch?

Paragraph IV litigation can delay a generic launch for up to 30 months after the NDA holder receives notice, subject to statutory conditions and court outcomes. Settlement agreements may provide:

• A fixed generic entry date
• A license before patent expiry
• Authorized-generic supply
• Restrictions by indication
• Supply or manufacturing terms
• No-admit liability provisions

The economic value of a settlement depends on the remaining patent term, probability of invalidity, expected price erosion and the first-filer position. For a product with multiple indications, a settlement may permit entry for some uses while preserving method-of-use restrictions for others.

Key Takeaways

• Human albumin is the principal excipient and a functional component of the nanoparticle delivery system.
• The core commercial differentiation is solvent-free, albumin-bound particle delivery rather than paclitaxel alone.
• Albumin quality, particle size, homogenization, lyophilization and reconstitution are the main technical control points.
• Abraxane is a small-molecule product subject to ANDA competition, not biosimilar competition.
• Early platform patent protection has expired, shifting value toward later claims, manufacturing know-how, regulatory history and supply reliability.
• Generic entry can produce rapid price erosion, especially with multiple approved suppliers.
• The strongest excipient opportunities are qualified albumin supply, recombinant albumin, particle-engineering services and contract sterile manufacturing.
• New albumin-bound products can use the platform for poorly soluble oncology compounds, but the regulatory and clinical burden remains substantial.

FAQs About Paclitaxel Protein-Bound Particle Excipients

Is human albumin in Abraxane therapeutically active?

Albumin functions as a carrier and particle-forming material. It is classified as an inactive ingredient in the finished drug product, but it materially affects formulation performance and delivery characteristics.

Can a generic manufacturer use a different albumin supplier?

A different supplier may be possible, but the applicant must demonstrate that the alternative albumin does not materially alter product quality, particle properties, stability, safety or performance.

Does Abraxane have biosimilar competition?

No. Abraxane contains the small molecule paclitaxel and is approved as a drug product. Competitors use the ANDA generic-drug pathway rather than the biosimilar pathway.

Can albumin-bound particles be used for non-oncology drugs?

Yes. The platform may be relevant to poorly soluble drugs in areas such as anti-infectives, immunology and central nervous system disorders. The new product would require its own regulatory, clinical and intellectual-property strategy.

What is the largest commercial barrier to launching a generic nab-paclitaxel product?

The principal barrier is reproducing the reference product’s particle and reconstitution characteristics at commercial scale while meeting sterile injectable manufacturing, regulatory and supply requirements.

References

1. U.S. Food and Drug Administration. (2023). Abraxane (paclitaxel protein-bound particles for injectable suspension) prescribing information.
2. U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,439,686: Composition and method for delivery of pharmacological agents.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: Abraxane, NDA 021660.
5. U.S. Courts. (n.d.). Public patent litigation records involving paclitaxel protein-bound particles and Abraxane.
6. U.S. Food and Drug Administration. (2022). FDA approves first generic of Abraxane.
7. U.S. Food and Drug Administration. (2024). Product-specific guidance for paclitaxel protein-bound particles for injectable suspension.
8. Bristol Myers Squibb. (2024). Annual report and product portfolio disclosures.